Evondos Factory Celebrates 10 Years - Focus on Development, Quality, and Team Spirit
Evondos, Europe's leading provider of automated medication dispensing services, is commemorating a significant milestone this year as its Salo factory reaches its 10th anniversary.
Evondos extends Icelandic deal by two more years
An agreement signed in 2021 to use Evondos medicine-dispensing robots in the home care sector in Iceland’s capital city of Reykjavik has recently been extended by two years.
Evondos and Medido join forces to improve home care in Europe
Automated medicine dispensing makes it possible for people to live independent lives at home with improved medication management and patient safety. Both Evondos and Medido, experts in automated medicine dispensing, are now joining forces to meet the increasing demand for medicine dispensing services. The two companies will help more people across Europe and beyond with a broader offering.
Impressive data from a pilot in Södertälje, Sweden, shows multiple benefits of using Evondos
Results from a four-year-long evaluation of Nordic biotech company Evondos’ pharmaceutical robots by Capio Närsjukvård in Södertälje reveal that patients are happier, the working environment of healthcare staff improved and valuable time was freed up for staff to perform other important tasks by spending less time dispensing medicines.
Evondos and Group Saltó signed a frame agreement for health robotics cooperation in Spain
Evondos, the leading provider of automated medicine dispensing services in the Nordics, and Group Saltó, a Spanish point of reference in technological services, have signed a frame agreement for cooperation in Spain. With the cooperation Evondos builds its capability to serve home care organizations in Spain. Evondos service ensures medicine adherence, safety, and support seniors to live independently at home.
Evondos secures €42M loan for global expansion plans
Evondos has secured a €42M loan from funds managed by the BlackRock Private Credit platform, in support of its global growth plans. The company continues to enjoy robust growth